Dose Escalation of Dexamethasone to Increase Duration of Transversus Abdominal Plane Block Following Cesarean Section

Model scores of the 29,894 trials active now.

Model score 17% for any early termination, 5% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 10% of the time (273 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2021-05-20. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: painhoursopioid48care
  Phrases that lowered it: dexamethasonedoseescalationcombinationgeneral
• Accepts healthy volunteers: Yes (lowers risk) · Who can join
• Sponsor's past termination rate: 12.5% (raises risk) · Sponsor's track record
• Trials the sponsor started in the prior 2 years: 93 (lowers risk) · Sponsor's track record
• Has a data monitoring committee: Yes (raises risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Phase: 2/3 (raises risk) · Design
• Design: parallel (raises risk) · Design
• Number of arms: 3 (lowers risk) · Design
• Minimum age: 18 (raises risk) · Who can join
• Primary purpose: treatment (raises risk) · Design
• Blinding: double (raises risk) · Design
• Disease area, cancer: No (lowers risk) · Disease area
• Sponsor's past trials: 240 (lowers risk) · Sponsor's track record
• Drugs with FDA adverse-event history: 5 (lowers risk) · Drug's FDA history
• Maximum age: not given (raises risk) · Who can join
• Drug's FAERS reports in the prior 12 months: 31025 (lowers risk) · Drug's FDA history
• Drug's FAERS reports before start: 140653 (lowers risk) · Drug's FDA history
• Responsible party: principal investigator (lowers risk) · Design
• Drug's FAERS reports marked serious: 86.4% (raises risk) · Drug's FDA history
• Collaborators: 0 (raises risk) · Design
• Drug's FAERS reports with a death: 23.8% (raises risk) · Drug's FDA history

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Dexamethasone Intravenous Versus Intrathecal in Spinal Anesthesia NCT05470530 · started 2022 · scored riskier than 5% of active trials completed
• Effect of TAP Block on Time Required for First Analgesic Dose After Cesarean Cection Under Spinal Anesthesia NCT04623632 · started 2020 · scored riskier than 10% of active trials completed
• MgSO4 as Adjuvants to Bupivacaine vs Neostigmine in TAP Block in Cesarean Section NCT06513013 · started 2023 · scored riskier than 7% of active trials completed
• Intravenous Ondansetron to Attenuate the Hypotensive, Bradycardic Response to Spinal Anesthesia in Healthy Parturients NCT01414777 · started 2009 · scored riskier than 14% of active trials completed
• Dexmedetomidine in Spinal Anesthesia Decreasing Post Spinal Shivering in Caesarean Section NCT06318546 · started 2024 · scored riskier than 6% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.